Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Liuying Township, Taiwan Clinical Trials

A listing of Liuying Township, Taiwan clinical trials actively recruiting patients volunteers.

RESULTS

Found (2981) clinical trials

This study is a Phase 1, open-label, dose escalation and cohort expansion study designed to characterize the safety, tolerability, PK, PD, immunogenicity, and preliminary anti-tumor activity of INCMGA00012 administered IV every two or four weeks in patients with relapsed/refractory, unresectable locally advanced or metastatic solid tumors.  The study consists of …

Phase

This study will be conducted to evaluate the therapeutic bioequivalence of a TEST formulation of calcipotriene hydrate and betamethasone dipropionate topical suspension 0.005%/0.064% to the RLD.

Phase

The purpose of this study is to evaluate the safety and tolerability of INCB050465 when combined with bendamustine and obinutuzumab in relapsed or refractory follicular lymphoma (FL).  

Phase

The purpose of this study is to evaluate the safety and tolerability of topical INCB018424 cream applied to pediatric subjects (≥ 12 to 17 years) with atopic dermatitis (AD).

Phase

This study will evaluate the safety and efficacy of NPT088 or Placebo in participants with probable Alzheimer's Disease

Phase

Phase 1 clinical research study for healthy Japanese adults

Phase

WCCT Global is seeking males and females ages 20 to 75 years old that are diagnosed with Osteopenia and currently on Glucocorticoids to participate in a clinical research study of an investigational drug. Your participation is necessary for new and innovative treatments for Osteopenia.

Phase

If you qualify, the study may involve 3 screening visits, 1 separate in-clinic stay of 5 days/4 nights and 10 outpatient visits. All study exams and procedures are provided at no cost to you. You do not need medical insurance to participate.

Phase

The purpose of this study is to measure safe and tolerable doses of rHIgM22 in patients with MS immediately following a relapse.

Phase